Literature DB >> 28993835

Delta Opioid Receptors and Modulation of Mood and Emotion.

Isaac J Dripps1, Emily M Jutkiewicz2.   

Abstract

Depression is a pervasive and debilitating mental disorder that is inadequately treated by current pharmacotherapies in a majority of patients. Although opioids have long been known to regulate mood states, the use of opioids to treat depression is rarely discussed. This chapter explores the preclinical and clinical evidence supporting the antidepressant-like effects of opioid ligands, and in particular, delta opioid receptor (DOR) agonists. DOR agonists have been shown to produce antidepressant-like effects in a number of animal models. Some DOR agonists also produce convulsions which has limited their clinical utility. However, DOR agonists that generate antidepressant-like effects without convulsions have recently been developed and these drugs are beginning to be evaluated in humans. Work investigating potential mechanisms of action for the antidepressant-like effects of DOR agonists is also explored. Understanding mechanisms that give rise to DOR-mediated behaviors is critical for the development of DOR drugs with improved safety and clinical utility, and future work should be devoted to elucidating these pathways.

Entities:  

Keywords:  Animal models; Antidepressant-like effects; Convulsions; Delta opioid receptor; Delta opioid receptor agonists; Enkephalin; Intracellular molecules; Mood; Neurotransmitters

Mesh:

Substances:

Year:  2018        PMID: 28993835     DOI: 10.1007/164_2017_42

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  7 in total

1.  Novel Dimethyltyrosine-Tetrahydroisoquinoline Peptidomimetics with Aromatic Tetrahydroisoquinoline Substitutions Show in Vitro Kappa and Mu Opioid Receptor Agonism.

Authors:  Deanna Montgomery; Jessica P Anand; Nicholas W Griggs; Thomas J Fernandez; Joshua G Hartman; Ashley A Sánchez-Santiago; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Neurosci       Date:  2019-07-01       Impact factor: 4.418

Review 2.  A review of opioid addiction genetics.

Authors:  Richard C Crist; Benjamin C Reiner; Wade H Berrettini
Journal:  Curr Opin Psychol       Date:  2018-08-09

Review 3.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

4.  Structure-Activity Relationships of 7-Substituted Dimethyltyrosine-Tetrahydroisoquinoline Opioid Peptidomimetics.

Authors:  Deanna Montgomery; Jessica P Anand; Mason A Baber; Jack J Twarozynski; Joshua G Hartman; Lennon J Delong; John R Traynor; Henry I Mosberg
Journal:  Molecules       Date:  2019-11-26       Impact factor: 4.411

Review 5.  Natural Products for the Treatment of Pain: Chemistry and Pharmacology of Salvinorin A, Mitragynine, and Collybolide.

Authors:  Soumen Chakraborty; Susruta Majumdar
Journal:  Biochemistry       Date:  2020-09-22       Impact factor: 3.162

6.  Delta opioid receptor activation modulates affective pain and modality-specific pain hypersensitivity associated with chronic neuropathic pain.

Authors:  Catherine M Cahill; Sarah V Holdridge; Shiwei Steve Liu; Lihua Xue; Claire Magnussen; Edmund Ong; Patrick Grenier; Anne Sutherland; Mary C Olmstead
Journal:  J Neurosci Res       Date:  2020-07-05       Impact factor: 4.164

7.  Delta-Opioid Receptors Play a Role in the Control of Selected Parameters Related to Stress and Brain Plasticity Under Non-stress and/or Stress Conditions.

Authors:  P Chomanic; L Karailievova; J Graban; D Jezova
Journal:  Cell Mol Neurobiol       Date:  2021-03-08       Impact factor: 5.046

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.